Genmab, the Danish biotechnology company, has announced that it’s partner Janssen Biotech Inc. will be starting a new Phase III trial of daratumumab as a frontline treatment for myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplantation. Daratumumab is an anti-CD38 monoclonal antibody with promising anti-myeloma activity that is currently being investigated in the relapsed setting. The trial will compare daratumumab in combination with Velcade, melphalan and prednisolone against Velcade, melphalan and prednisolone, and is expected to recruit 700 patients worldwide.

Read the full article